Coherus Oncology Statistics
 Total Valuation
 CHRS has a market cap or net worth of $197.59 million. The enterprise value is $978,368.
 Important Dates
 The next confirmed earnings date is Thursday, November 6, 2025, after market close.
 | Earnings Date | Nov 6, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 CHRS has 116.23 million shares outstanding. The number of shares has increased by 6.04% in one year.
 | Current Share Class | 116.23M | 
| Shares Outstanding | 116.23M | 
| Shares Change (YoY) | +6.04% | 
| Shares Change (QoQ) | +0.19% | 
| Owned by Insiders (%) | 4.32% | 
| Owned by Institutions (%) | 47.50% | 
| Float | 111.19M | 
Valuation Ratios
 The trailing PE ratio is 1.09.
 | PE Ratio | 1.09 | 
| Forward PE | n/a | 
| PS Ratio | 0.72 | 
| Forward PS | 2.47 | 
| PB Ratio | 1.65 | 
| P/TBV Ratio | 2.93 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | 0.01 | 
| EV / Sales | 0.00 | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.34.
 | Current Ratio | 1.44 | 
| Quick Ratio | 1.36 | 
| Debt / Equity | 0.34 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | -3.63 | 
Financial Efficiency
 Return on equity (ROE) is 331.11% and return on invested capital (ROIC) is -29.48%.
 | Return on Equity (ROE) | 331.11% | 
| Return on Assets (ROA) | -9.92% | 
| Return on Invested Capital (ROIC) | -29.48% | 
| Return on Capital Employed (ROCE) | -50.32% | 
| Revenue Per Employee | $1.19M | 
| Profits Per Employee | $788,382 | 
| Employee Count | 228 | 
| Asset Turnover | 0.49 | 
| Inventory Turnover | 3.61 | 
Taxes
  | Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has increased by +128.68% in the last 52 weeks. The beta is 0.98, so CHRS's price volatility has been similar to the market average.
 | Beta (5Y) | 0.98 | 
| 52-Week Price Change | +128.68% | 
| 50-Day Moving Average | 1.51 | 
| 200-Day Moving Average | 1.10 | 
| Relative Strength Index (RSI) | 54.09 | 
| Average Volume (20 Days) | 1,007,452 | 
Short Selling Information
 The latest short interest is 30.17 million, so 25.95% of the outstanding shares have been sold short.
 | Short Interest | 30.17M | 
| Short Previous Month | 31.14M | 
| Short % of Shares Out | 25.95% | 
| Short % of Float | 27.13% | 
| Short Ratio (days to cover) | 23.04 | 
Income Statement
 In the last 12 months, CHRS had revenue of $272.21 million and earned $179.75 million in profits. Earnings per share was $1.55.
 | Revenue | 272.21M | 
| Gross Profit | 151.86M | 
| Operating Income | -88.48M | 
| Pretax Income | 59.13M | 
| Net Income | 179.75M | 
| EBITDA | -83.83M | 
| EBIT | -88.48M | 
| Earnings Per Share (EPS) | $1.55 | 
 Full Income StatementBalance Sheet
 The company has $237.64 million in cash and $41.03 million in debt, giving a net cash position of $196.61 million or $1.69 per share.
 | Cash & Cash Equivalents | 237.64M | 
| Total Debt | 41.03M | 
| Net Cash | 196.61M | 
| Net Cash Per Share | $1.69 | 
| Equity (Book Value) | 119.83M | 
| Book Value Per Share | 1.03 | 
| Working Capital | 116.58M | 
 Full Balance SheetCash Flow
  | Operating Cash Flow | -105.87M | 
| Capital Expenditures | n/a | 
| Free Cash Flow | -105.87M | 
| FCF Per Share | -$0.91 | 
 Full Cash Flow StatementMargins
 Gross margin is 55.79%, with operating and profit margins of -32.50% and 66.03%.
 | Gross Margin | 55.79% | 
| Operating Margin | -32.50% | 
| Pretax Margin | 21.72% | 
| Profit Margin | 66.03% | 
| EBITDA Margin | -30.80% | 
| EBIT Margin | -32.50% | 
| FCF Margin | n/a | 
Dividends & Yields
 CHRS does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -6.04% | 
| Shareholder Yield | -6.04% | 
| Earnings Yield | 90.97% | 
| FCF Yield | -53.58% | 
 Analyst Forecast
 The average price target for CHRS is $4.51, which is 165.29% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $4.51 | 
| Price Target Difference | 165.29% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 4 | 
| Revenue Growth Forecast (5Y) | -2.84% | 
| EPS Growth Forecast (5Y) | n/a | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value |  | 
| Lynch Upside |  | 
| Graham Number |  | 
| Graham Upside |  | 
Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
 CHRS has an Altman Z-Score of -3.65 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
 | Altman Z-Score | -3.65 | 
| Piotroski F-Score | 5 |